Tuesday Mar 11
Applied Clinical Trials
BioClinica Technology Supports Pharmacyclics in Achieving Early...
The Phase III clinical program supporting IMBRUVICA's early approval contained data that was collected and managed with BioClinica's web-based solution and provided the Pharmacyclics team instant online access to review and analyze clinical data as it was captured in this global study, which involved 391 patients and was conducted at clinical sites ... (more)
Trending on the Topix Network
Sun Mar 09, 2014
Pharmacyclics: 7 Different Insiders Have Sold Shares During The Last 30 Days
Pharmacyclics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune-mediated diseases.
Fri Feb 28, 2014
Pharmacyclics Director Unloads $11,559,576 in Stock
Pharmacyclics Director Den Broek Richard Van sold 78,835 shares of the stock in a transaction dated Thursday, February 27th.
Thu Feb 27, 2014
The Motley Fool
Can Pharmacyclics, Inc.'s Imbruvica Stay Ahead of Gilead Sciences, Inc.'s Idelalisib?
Analysts are predicting some impressive sales, and the market has noticed. The company's stock price has risen over 40% this year, while the broad market remained somewhat flat.
Tue Feb 25, 2014
The Motley Fool
1 Drug Critical to Johnson & Johnson's Future Success
The wins are coming courtesy of the cancer drug ibrutinib, a compound that's already won approval from the FDA as a treatment for both mantle cell leukemia and chronic lymphocytic leukemia.
Mon Feb 24, 2014
Pharmacyclics Receives "Neutral" Rating from Zacks
's stock had its "neutral" rating reiterated by Zacks in a research report issued on Monday, AnalystRatingsNetwork reports.
Zacks' Bull Of The Day: Alexion Pharma
Biotechnology was full of success stories in 2013. And some of those stories just got more exciting in February as the Nasdaq Biotech Index rallied 13% off the lows.
Fri Feb 21, 2014
Investor's Business Daily
Pharmacyclics Hits High As Imbruvica Launches Big
Late Thursday, the company said Imbruvica garnered $13.6 million in net sales in the quarter, drawn from just six weeks on the market since it was approved for mantle-cell lymphoma in mid-November.
Pharmacyclics boosted at Nomura
Q4 results confirmed a strong launch for Imbruvica despite just six weeks on the market and approval in the smaller indication of relapsed/refractory mantle cell lymphoma, says analyst Robert Drbui, reiterating his Buy rating and raising the PT to $166 from $137.
Thu Feb 20, 2014
Pharmacyclics (PCYC) Releases Quarterly Earnings, Beats Expectations By $0.28 EPS
Pharmacyclics announced its earnings results on Thursday. The company reported $0.95 earnings per share for the quarter, beating the analysts' consensus estimate of $0.67 by $0.28, American Banking News reports.
Mon Feb 17, 2014
Pharmacyclics, Inc. Announces Date Of Conference Call To Discuss...
Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify and control promising product candidates based on scientific development and administrational ... (more)
Fri Feb 14, 2014
Pharmacyclics Announces Date of Conference call to discuss Financial...
Pharmacyclics, Inc. today announced that it will hold a conference call and audio webcast to discuss financial results for its fourth quarter and full year ended December 31, 2013 after the NASDAQ Market closes on Thursday, February 20, 2014 at 4:30 p.m. ET.
FDA approves new leukemia drug; may one day make chemo obsolete for some CLL patients
A new drug for patients with chronic lymphocytic leukemia , or CLL, approved this week by the Food and Drug Administration, could signal a drastic change in the way the disease is treated.
Thu Feb 13, 2014
Five Star Equities Issues New Research Reports on AMZN, FOSL, PCYC...
Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns.
Pharmacyclics Given New $166.00 Price Target at Roth Capital
Roth Capital's price objective would suggest a potential upside of 25.75% from the company's current price.